Clinical Trial Update: CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy [Phase 1, Phase 2]

View source ↗

Summary

The CREATE trial evaluating cabotegravir and rilpivirine for HIV-1 infection in pregnancy (Phase 1/Phase 2) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cabotegravir (cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection, Pregnancy | Phase 1, Phase 2 | Status: WITHDRAWN